Cyclerion Therapeutics (CYCN) Expected to Release Earnings on Tuesday

Cyclerion Therapeutics (NASDAQ:CYCN) is projected to release its results before the market opens on Tuesday, August 4th. Analysts expect Cyclerion Therapeutics to announce earnings of ($7.10) per share and revenue of $1.50 million for the quarter.

Cyclerion Therapeutics (NASDAQ:CYCN) last issued its quarterly earnings results on Tuesday, May 12th. The company reported ($0.76) EPS for the quarter, topping analysts’ consensus estimates of ($17.20) by $16.44. Cyclerion Therapeutics had a negative return on equity of 62.10% and a negative net margin of 170.11%. On average, analysts expect Cyclerion Therapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Cyclerion Therapeutics Price Performance

Shares of NASDAQ:CYCN opened at $3.48 on Tuesday. The company has a market capitalization of $15.07 million, a PE ratio of -2.56 and a beta of 1.74. The business has a fifty day moving average price of $3.33 and a two-hundred day moving average price of $2.54. Cyclerion Therapeutics has a 1 year low of $1.03 and a 1 year high of $8.48.

Institutional Investors Weigh In On Cyclerion Therapeutics

A hedge fund recently bought a new stake in Cyclerion Therapeutics stock. Two Sigma Investments LP purchased a new position in Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund purchased 13,293 shares of the company’s stock, valued at approximately $31,000. Two Sigma Investments LP owned 0.40% of Cyclerion Therapeutics at the end of the most recent quarter. Institutional investors own 75.62% of the company’s stock.

Analyst Ratings Changes

Separately, Weiss Ratings upgraded Cyclerion Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Wednesday, April 29th. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat, the stock has a consensus rating of “Sell”.

About Cyclerion Therapeutics

Cyclerion Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of inhibitors and stimulators of soluble guanylate cyclase (sGC), an intracellular enzyme that plays a critical role in the regulation of vascular tone, cellular proliferation and inflammation. By targeting the nitric oxide (NO)–sGC–cyclic guanosine monophosphate (cGMP) signaling pathway, Cyclerion aims to address a range of cardiometabolic, cardiovascular, pulmonary and neurological disorders with significant unmet medical need.

The company’s lead program, praliciguat, is an oral sGC stimulator investigated for indications such as diabetic nephropathy, metabolic syndrome and heart failure with preserved ejection fraction.